<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02369510</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 14-2058</org_study_id>
    <nct_id>NCT02369510</nct_id>
  </id_info>
  <brief_title>Does the Addition of Epinephrine Prolong the Duration of Spinal Anesthesia for Repeat Cesarean Section?</brief_title>
  <official_title>Does the Addition of Epinephrine Increase the Duration of Intrathecal Hyperbaric Bupivacaine for Repeat Cesarean Section?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether the addition of a medication called
      epinephrine to spinal medications prolongs the duration of the anesthesia. The medication
      standardly used in spinal anesthesia is a local anesthetic (bupivacaine) and an opiate pain
      medication (morphine). These medications typically last about 2 hours. The investigators want
      to determine if adding epinephrine to the spinal medications prolongs the anesthetic without
      side effects. A longer duration of anesthesia may be useful in prolonged repeat cesarean
      section. Epinephrine is known to prolong the action of some local anesthetics, but the
      investigators want to specifically study combining it with the medications the investigators
      use regularly for cesarean section.

      You may qualify to take part in this research study because you are having a repeat cesarean
      section. Repeat cesarean sections sometimes last longer than 2 hours. The investigators want
      to determine if epinephrine will prolong the anesthetic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal anesthesia with bupivacaine is a commonly used anesthetic in the obstetric population.
      It is most frequently carried out as a single shot intrathecal injection. This method can be
      utilized for both labor analgesia and surgical anesthesia for cesarean section. One of the
      concerns in using a single shot spinal injection for surgical anesthesia is the duration of
      adequate surgical conditions. This concern is especially relevant to repeat cesarean
      sections, as each subsequent procedure has the potential to be more complex than the prior
      and, therefore, prolonged. A reliable way to prolong surgical anesthesia provided by single
      shot spinal injection of bupivacaine could prove invaluable in the setting of repeat cesarean
      section. It has been well documented that adding epinephrine to intrathecal lidocaine will
      increase its duration1, but the evidence for augmenting the duration of anesthesia provided
      by adding epinephrine to bupivacaine is much more equivocal and less robust. This is a
      randomized control trial investigating whether or not adding epinephrine to a standard single
      intrathecal injection of hyperbaric bupivacaine for repeat cesarean will prolong its
      duration. It will be investigated using women who are undergoing scheduled repeat cesarean
      section in whom neuraxial anesthesia is the appropriate primary anesthetic. The investigators
      will compare the onset, quality and duration of both sensory and motor components of the
      spinal block as well as the incidence of known side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensory Recovery</measure>
    <time_frame>up to 3 hours</time_frame>
    <description>Time to T10 sensory recovery as measured by pinprick sensation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor Recovery</measure>
    <time_frame>up to 4 hours</time_frame>
    <description>Time to Bromage 3 motor recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Block Onset</measure>
    <time_frame>up to 15 min</time_frame>
    <description>Time to a onset of T4 level of anesthesia or the highest level achieved in 15min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hypotension</measure>
    <time_frame>at 2 minutes and at 25 minutes</time_frame>
    <description>Incidence of hypotension as measured by participants needing vasopressor agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequacy of Anesthesia</measure>
    <time_frame>up to 3 hrs</time_frame>
    <description>As measured by pinprick sensation and/or patient discomfort as measured by verbal pain score on a scale of 0=no pain to 10=worst imaginable pain, obtained within 3 hours of receiving anesthesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>up to 3 hours</time_frame>
    <description>Patient satisfaction score was elicited upon arrival to the recovery room on a 1-5 Likert scale. Number of participants selecting the highest score of 5 or &quot;completely satisfied&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Nausea and Vomiting</measure>
    <time_frame>up to 3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Pruritus</measure>
    <time_frame>up to 3 hours</time_frame>
    <description>data not collected</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Spinal Anesthesia</condition>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Low-dose epinephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100micrograms of epinephrine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose epinephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200micrograms of epinephrine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No epinephrine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.2ml saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose epinephrine</intervention_name>
    <description>0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
    <arm_group_label>Low-dose epinephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose epinephrine</intervention_name>
    <description>0.2ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
    <arm_group_label>High-dose epinephrine</arm_group_label>
    <other_name>adrenaline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No epinephrine</intervention_name>
    <description>0.2ml of preservative-free saline will be added to the standard spinal medications</description>
    <arm_group_label>No epinephrine</arm_group_label>
    <other_name>preservative-free saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-emergent repeat cesarean section

          -  Neuraxial anesthesia as the planned primary anesthetic

          -  Informed consent obtained

          -  Females age 18-50

        Exclusion Criteria:

          -  Emergency cesarean section

          -  Anesthetic other than neuraxial

          -  Allergy to local anesthetics, morphine, or epinephrine

          -  Pre-existing sensory/motor deficit
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yaakov Beilin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2015</study_first_posted>
  <results_first_submitted>May 1, 2017</results_first_submitted>
  <results_first_submitted_qc>August 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 30, 2017</results_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Daniel Katz</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>spinal anesthesia</keyword>
  <keyword>epinephrine</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>repeat cesarean</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low-dose Epinephrine</title>
          <description>100micrograms of epinephrine group
Low-dose epinephrine: 0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
        </group>
        <group group_id="P2">
          <title>High-dose Epinephrine</title>
          <description>200micrograms of epinephrine group
High-dose epinephrine: 0.2ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
        </group>
        <group group_id="P3">
          <title>No Epinephrine</title>
          <description>0.2ml saline
No epinephrine: 0.2ml of preservative-free saline will be added to the standard spinal medications</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Spilled Medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Epidural Activation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low-dose Epinephrine</title>
          <description>100micrograms of epinephrine group
Low-dose epinephrine: 0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
        </group>
        <group group_id="B2">
          <title>High-dose Epinephrine</title>
          <description>200micrograms of epinephrine group
High-dose epinephrine: 0.2ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
        </group>
        <group group_id="B3">
          <title>No Epinephrine</title>
          <description>0.2ml saline
No epinephrine: 0.2ml of preservative-free saline will be added to the standard spinal medications</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="3.86"/>
                    <measurement group_id="B2" value="34" spread="5.19"/>
                    <measurement group_id="B3" value="34" spread="5.12"/>
                    <measurement group_id="B4" value="34" spread="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-op Systolic Blood Pressure (SBP)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116" spread="12"/>
                    <measurement group_id="B2" value="119" spread="10"/>
                    <measurement group_id="B3" value="115" spread="11"/>
                    <measurement group_id="B4" value="117" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-op Diastolic Blood Pressure (DBP)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" spread="11"/>
                    <measurement group_id="B2" value="70" spread="9"/>
                    <measurement group_id="B3" value="66" spread="8"/>
                    <measurement group_id="B4" value="70" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-op Heart Rate (HR)</title>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82" spread="10"/>
                    <measurement group_id="B2" value="85" spread="9"/>
                    <measurement group_id="B3" value="78" spread="10"/>
                    <measurement group_id="B4" value="82" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensory Recovery</title>
        <description>Time to T10 sensory recovery as measured by pinprick sensation</description>
        <time_frame>up to 3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Epinephrine</title>
            <description>100micrograms of epinephrine group
Low-dose epinephrine: 0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O2">
            <title>High-dose Epinephrine</title>
            <description>200micrograms of epinephrine group
High-dose epinephrine: 0.2ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O3">
            <title>No Epinephrine</title>
            <description>0.2ml saline
No epinephrine: 0.2ml of preservative-free saline will be added to the standard spinal medications</description>
          </group>
        </group_list>
        <measure>
          <title>Sensory Recovery</title>
          <description>Time to T10 sensory recovery as measured by pinprick sensation</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135" lower_limit="120" upper_limit="150"/>
                    <measurement group_id="O2" value="165" lower_limit="150" upper_limit="180"/>
                    <measurement group_id="O3" value="120" lower_limit="45" upper_limit="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Motor Recovery</title>
        <description>Time to Bromage 3 motor recovery</description>
        <time_frame>up to 4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Epinephrine</title>
            <description>100micrograms of epinephrine group
Low-dose epinephrine: 0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O2">
            <title>High-dose Epinephrine</title>
            <description>200micrograms of epinephrine group
High-dose epinephrine: 0.2ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O3">
            <title>No Epinephrine</title>
            <description>0.2ml saline
No epinephrine: 0.2ml of preservative-free saline will be added to the standard spinal medications</description>
          </group>
        </group_list>
        <measure>
          <title>Motor Recovery</title>
          <description>Time to Bromage 3 motor recovery</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150" lower_limit="135" upper_limit="150"/>
                    <measurement group_id="O2" value="172" lower_limit="150" upper_limit="210"/>
                    <measurement group_id="O3" value="120" lower_limit="105" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Block Onset</title>
        <description>Time to a onset of T4 level of anesthesia or the highest level achieved in 15min</description>
        <time_frame>up to 15 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Epinephrine</title>
            <description>100micrograms of epinephrine group
Low-dose epinephrine: 0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O2">
            <title>High-dose Epinephrine</title>
            <description>200micrograms of epinephrine group
High-dose epinephrine: 0.2ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O3">
            <title>No Epinephrine</title>
            <description>0.2ml saline
No epinephrine: 0.2ml of preservative-free saline will be added to the standard spinal medications</description>
          </group>
        </group_list>
        <measure>
          <title>Block Onset</title>
          <description>Time to a onset of T4 level of anesthesia or the highest level achieved in 15min</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="6" upper_limit="8"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="8"/>
                    <measurement group_id="O3" value="8" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hypotension</title>
        <description>Incidence of hypotension as measured by participants needing vasopressor agents</description>
        <time_frame>at 2 minutes and at 25 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Epinephrine</title>
            <description>100micrograms of epinephrine group
Low-dose epinephrine: 0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O2">
            <title>High-dose Epinephrine</title>
            <description>200micrograms of epinephrine group
High-dose epinephrine: 0.2ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O3">
            <title>No Epinephrine</title>
            <description>0.2ml saline
No epinephrine: 0.2ml of preservative-free saline will be added to the standard spinal medications</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypotension</title>
          <description>Incidence of hypotension as measured by participants needing vasopressor agents</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adequacy of Anesthesia</title>
        <description>As measured by pinprick sensation and/or patient discomfort as measured by verbal pain score on a scale of 0=no pain to 10=worst imaginable pain, obtained within 3 hours of receiving anesthesia.</description>
        <time_frame>up to 3 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Epinephrine</title>
            <description>100micrograms of epinephrine group
Low-dose epinephrine: 0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O2">
            <title>High-dose Epinephrine</title>
            <description>200micrograms of epinephrine group
High-dose epinephrine: 0.2ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O3">
            <title>No Epinephrine</title>
            <description>0.2ml saline
No epinephrine: 0.2ml of preservative-free saline will be added to the standard spinal medications</description>
          </group>
        </group_list>
        <measure>
          <title>Adequacy of Anesthesia</title>
          <description>As measured by pinprick sensation and/or patient discomfort as measured by verbal pain score on a scale of 0=no pain to 10=worst imaginable pain, obtained within 3 hours of receiving anesthesia.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Patient satisfaction score was elicited upon arrival to the recovery room on a 1-5 Likert scale. Number of participants selecting the highest score of 5 or &quot;completely satisfied&quot;.</description>
        <time_frame>up to 3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Epinephrine</title>
            <description>100micrograms of epinephrine group
Low-dose epinephrine: 0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O2">
            <title>High-dose Epinephrine</title>
            <description>200micrograms of epinephrine group
High-dose epinephrine: 0.2ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O3">
            <title>No Epinephrine</title>
            <description>0.2ml saline
No epinephrine: 0.2ml of preservative-free saline will be added to the standard spinal medications</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Patient satisfaction score was elicited upon arrival to the recovery room on a 1-5 Likert scale. Number of participants selecting the highest score of 5 or &quot;completely satisfied&quot;.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Nausea and Vomiting</title>
        <time_frame>up to 3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Epinephrine</title>
            <description>100micrograms of epinephrine group
Low-dose epinephrine: 0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O2">
            <title>High-dose Epinephrine</title>
            <description>200micrograms of epinephrine group
High-dose epinephrine: 0.2ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O3">
            <title>No Epinephrine</title>
            <description>0.2ml saline
No epinephrine: 0.2ml of preservative-free saline will be added to the standard spinal medications</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Nausea and Vomiting</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Pruritus</title>
        <description>data not collected</description>
        <time_frame>up to 3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Epinephrine</title>
            <description>100micrograms of epinephrine group
Low-dose epinephrine: 0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O2">
            <title>High-dose Epinephrine</title>
            <description>200micrograms of epinephrine group
High-dose epinephrine: 0.2ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
          </group>
          <group group_id="O3">
            <title>No Epinephrine</title>
            <description>0.2ml saline
No epinephrine: 0.2ml of preservative-free saline will be added to the standard spinal medications</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Pruritus</title>
          <description>data not collected</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Low-dose Epinephrine</title>
          <description>100micrograms of epinephrine group
Low-dose epinephrine: 0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
        </group>
        <group group_id="E2">
          <title>High-dose Epinephrine</title>
          <description>200micrograms of epinephrine group
High-dose epinephrine: 0.2ml of 1:1000 epinephrine will be added to the standard spinal medications</description>
        </group>
        <group group_id="E3">
          <title>No Epinephrine</title>
          <description>0.2ml saline
No epinephrine: 0.2ml of preservative-free saline will be added to the standard spinal medications</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Katz</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-7475</phone>
      <email>Daniel.Katz@MountSinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

